ArticleGland surgery2026
Use of lateral intercostal artery perforator flaps in breast-conserving surgery for breast cancer: a single-center experience.
Article in Gland surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast-conserving surgery (BCS) combined with radiotherapy has become a standard treatment for early-stage breast cancer, providing oncologic outcomes comparable to mastectomy while preserving breast aesthetics. However, large-volume resections may result in contour deformities and poor cosmetic outcomes. Perforator flaps such as the lateral intercostal artery perforator (LICAP) and anterior intercostal artery perforator (AICAP) flaps have emerged as valuable oncoplastic techniques for immediate volume replacement. This study aimed to report a single-center experience using LICAP and AICAP flaps following BCS. Methods: A retrospective observational single-center study was performed between April 2024 and April 2025. Consecutive patients undergoing BCS with immediate reconstruction using LICAP or AICAP flaps were included. Demographic data, tumor characteristics, surgical outcomes, complications, aesthetic results, and timing of adjuvant therapy were analyzed. Descriptive statistics were used. Results: Fifteen patients underwent reconstruction, predominantly using LICAP flaps (93.3%), with a single case of AICAP reconstruction (6.7%). Invasive carcinoma was identified in 73.3% of cases, with a mean tumor size of 41.7 mm. All flaps remained viable, with no cases of partial or total necrosis. All patients initiated adjuvant therapy within 12 weeks postoperatively. After a mean follow-up of 20 months, no local recurrences were observed. Conclusions: LICAP flap reconstruction may represent a feasible and effective option for immediate volume replacement following BCS in selected patients. However, these findings must be interpreted within the context of the study's limitations, due to the small sample size, lack of a control group, and limited follow-up. Further studies with larger cohorts and longer follow-up are required to confirm these preliminary results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.